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Introduction: Dietary factors that help control perceived hunger might improve adherence to calorie-reduced diets.
Objectives: The objective of the study was to investigate the effect of supplementing a three-day, low-calorie diet with
PolyGlycopleX (PGX), a highly viscous fibre, on subjective ratings of appetite compared with a placebo.
Methods: In a double-blind crossover design with a 3-week washout, 45 women (aged 38±9 years, body mass index
29.9±2.8kgm
 2) were randomised to consume a 1000-kcal per day diet for 3 days, supplemented with 5g of PGX or placebo
at each of breakfast, lunch and dinner. Subjective appetite was assessed using 100mm visual analogue scales that were
completed daily before, between and after consumption of meals.
Results: Thirty-five women completed the study. Consumption of PGX compared with placebo led to significantly lower mean
area under the curve for hunger on day 3 (440.4 versus 375.4; P¼0.048), prospective consumption on day 3 (471.0 versus
401.8; P¼0.017) and the overall 3-day average (468.6 versus 420.2; P¼0.026). More specifically, on day 3 PGX significantly
reduced total appetite, hunger, desire to eat and prospective consumption for 2.5 and 4.5h after lunch and before dinner times,
with hunger also being reduced 2.5h after dinner (Po0.05).
Conclusion: The results show that adding 5g of PGX to meals during consumption of a low-calorie diet reduces subjective
ratings of prospective consumption and increases the feelings of satiety, especially during afternoon and evening. This highly
viscous polysaccharide may be a useful adjunct to weight-loss interventions involving significant caloric reductions.
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Introduction
Obesity increases the risk of type 2 diabetes, cardiovascular
disease and other chronic diseases.
1,2 Weight reduction is
associated with significant improvements in blood pressure,
serum cholesterol levels and glycaemic control.
3 Achieving
negative energy balance is an important factor in determin-
ing the magnitude and rate of weight loss.
4 Calorie-restricted
diets, ideally combined with exercise and behaviour mod-
ification, are considered to be the initial treatment strategy
for overweight and obese individuals. Low-calorie diets at a
level of 1000–1200kcal per day for most overweight women
and 1200–1600kcal per day for most overweight men are
often recommended for weight loss.
5 With low-calorie diets,
maintaining satiety is critical, as perceived hunger has been
shown to be a significant predictor of failure to lose weight.
6
After weight loss is achieved, appetite often increases leading
to refractory weight gain.
7 Identifying factors that suppress
appetite is important for successful weight loss and main-
tenance.
Increased fibre intake has been associated with reduced
energy intake and increased satiety, and may be an
important factor in obesity management.
8 A meta-analysis
of 22 studies concluded that consumption of 14g of fibre per
day resulted in a 10% decrease in energy intake and a 1.9-kg
weight loss over 3.8 months.
9 Viscous soluble fibres, in
particular, appear to increase satiety
10–14 and promote
adherence to calorie-reduced diets.
15,16 Accordingly, con-
suming substantial quantities of viscous dietary fibre may
provide significant therapeutic benefits under conditions of
reduced energy intake. However, as the benefit of these fibres Received 6 October 2011; accepted 24 October 2011
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17 their acceptance is often hampered
by issues of palatability.
18
Recently, PolyGlycopleX (PGX), a novel, highly viscous
non-starch polysaccharide complex has been developed for
human consumption. This soluble dietary fibre displays
delayed viscosity for 15–30min after ingestion, thus, allow-
ing for a more palatable and easy-to-use functional fibre.
In a recent randomised, placebo-controlled trial, PGX was
shown to diminish hunger and reduce ad libitum food
consumption compared with less viscous fibres (cellulose
and glucomannan) given in meal-replacement drinks.
19 The
objective of this study was to investigate the effect of supple-
menting a three-day low-calorie diet with PGX on subjective
ratings of appetite compared with a placebo in overweight
and obese women.
Materials and methods
Subjects
Subjects were recruited through local newspaper advertise-
ments. Women with a body mass index between 25 and
34.9kgm
 2 and between 20 and 50 years of age were eligible
to participate. Exclusion criteria included: pregnancy or
lactation, smoking, consumption of more than two alcoholic
drinks daily or nine alcoholic drinks weekly, recent partici-
pation in a calorie-reduced diet, the presence of chronic
diseases, past history of gastrointestinal surgery, a change in
body weight of more than 3kg during the last 3 months,
hypersensitivity to the study foods, taking medication or
natural health products, which may affect gastrointestinal
motility hunger or appetite. Furthermore excluded were
those who scored 9 or more on the restraint scale; 27 or
above for uncontrolled eating, or 18 or greater for emotional
eating on the Three-Factor Eating Questionnaire-R18V2,
validated for Canadian and US obese and non-obese
individuals.
20 As lower palatability of foods may diminish
the sensation of hunger and desire to eat,
21 a Food Preference
Questionnaire was used to ensure that all the participants
expressed acceptance of the foods included in the study.
Those scoring less than 3 for more than 50% of the food
items were excluded from the study. The University of British
Columbia Research Ethics Committee approved the study
and all subjects gave informed consent to participate.
Study supplements
PGX (a-D-glucurono-a-D-manno-b-D-manno-b-D-gluco), (a-L-
gulurono-b-D mannurono), b-D-gluco-b-D-mannan (Inovo-
biologic, Calgary, Alberta, Canada) is a novel functional
fibre complex
22,23 manufactured by a proprietary process
from three fibres (konjac (glucomannan), sodium alginate
and xanthan gum) to form a highly viscous polysaccha-
ride (higher viscosity than any currently known individual
polysaccharide or fibre blend) with high water-holding and
gel-forming properties. PGX has been shown to be safe and
well tolerated in rodents
24 and in humans.
25 Genotoxicity
studies of PGX have shown no mutagenic effects using
bacterial reverse mutation and mouse micronucleus assays.
26
PGX is 87.4% dietary fibre, of which 81.8% is soluble. It can
be sprinkled on food before consumption or taken with soup
or beverage before meals. Rice flour was used as a placebo
and has been used in other clinical trials for its white colour,
neutral taste and hypoallergenicity.
27,28 PGX and rice flour
both consist of approximately similar carbohydrate content
with carbohydrate in PGX being dietary fibre and in rice
flour being starch. Boiling or other forms of moist heat
processing is required for rice flour to be effectively digested.
Without cooking, only about 1% of the starch in raw rice
flour is digested.
29 Therefore, the carbohydrate in uncooked
rice flour is essentially dietary fibre resulting in rice flour’s
caloric value that closely approximates PGX. Both study
supplements were packaged with clear plastic scoops in
white plastic containers containing 100g and were indis-
tinguishable from each other.
Study design/protocol
The study was a prospective, randomised, double-blind,
placebo-controlled crossover trial. The study had two
experimental phases with a 3-week washout. Test periods
were on the same days of the week (Tuesday–Thursday) and
were conducted during the follicular phase (days 4–10) of the
women’s menstrual cycle to minimise hormonal influences
on eating/feeding behaviour and appetite.
30 On Monday of
the test week, subjects attended the clinic where their
bodyweight was measured, study food was provided and
they were randomised to either the test or placebo supple-
ment. During the test period, subjects consumed the break-
fasts, lunches and dinners provided immediately after the
food was sprinkled with 5g of supplement or placebo.
Participants completed visual analogue scales (VAS) ques-
tionnaires at specified times (see below). To avoid a second
meal effect and to minimise differences in glycogen stores,
the night before consumption of the 3-day low-calorie diet,
all subjects consumed the same evening meal. In addition,
participants were instructed not to consume alcohol or
engage in vigorous physical activity 48h before consuming
the low-calorie diet. On Friday, subjects returned to the clinic
to have their compliance assessed, documents reviewed and
to have any adverse effects recorded. To assess compliance,
subjects kept a log of daily food and study product consumed
and returned the product containers for weighing.
Low-calorie diet
A three-day structured low-calorie diet of 1000kcal per day
was provided with the intention that caloric restriction
would accentuate feelings of hunger. The low-calorie diet
was designed to provide participants with 65% of energy
as carbohydrate, 10% protein, and 15% fat (Appendix 1).
Commercially available frozen dinner entrees (President’s
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Nutrition and DiabetesChoice Blue Menu, Loblaw, Ontario, Canada) were provided
to participants to standardise caloric intake and macronu-
trient composition.
Subjective appetite measures
Rating subjective appetite using VAS is a valid and reliable
measure of appetite under both experimental and free-living
conditions, especially when using a within-subject design, as
used in the current study.
31,32 VAS ratings were made on a
100-mm scale with words anchored at either end in the
following order: first, ‘How strong is your desire to eat?’ (Very
strongFVery weak); second, ‘How hungry do you feel?’ (Not
hungry at allFVery hungry); third, ‘How full do you feel?’
(Very fullFNot at all full); and fourth, ‘How much food do
you think you could eat?’ (A large amount–Nothing at all),
which assesses prospective consumption. The palatability of
the meals was also evaluated after meals by a fifth question
asking ‘How would you rate the overall palatability of the
food? (UnpalatableFVery palatable). The times of rating
were the same every day for both phases; however, to work
with participants at various schedules, different start times in
the morning were available. VAS were completed before
(e.g., 0755h) and after breakfast (e.g., 0830h), in between
the morning meals (e.g., 1030h), before (e.g., 1225h) and
after (e.g.,1300h) lunch, in between meals in the afternoon
(e.g., 1500h, 1700h), before (e.g., 1725h) and after (e.g.,
1800h) dinner and in the evening (e.g., 2000h). Participants
were provided with programmable alert wrist watches
(CADEX Medication reminder watch, e-pill, LLC., Wellesley,
MA, USA) to remind them when to eat and when to
complete the questionnaires. Participants were allowed
20min to consume the food, supplement and 500ml of
water, and were allowed to consume an additional 500 ml of
water between meals. Participants were instructed not to
consume water 30min before completing premeal VAS. All
food and water consumed during Phase 1 was recorded and
the same amount was provided for Phase 2.
Statistical analyses
Changes in weight over each test period were tested for
differences between treatment groups using the Wilcoxon
rank sum test. For compliance, the P-values of differences
between the two treatment groups within a single period
were calculated from two-sample t-tests; the statistical test
for the summary across both periods of data used a linear
mixed model approach, which took into consideration that
the same participants appeared once on each of the two
treatments (due to the crossover design). For VAS score
analyses, the area under the curve was analysed on the log
scale to meet the distributional assumptions required for the
statistical methods. The treatment effect was estimated from
a linear mixed-effects model to take into consideration the
crossover design of the study; the model was adjusted for
phase, treatment, randomised sequence and a within-patient
comparison was made to assess the treatment effect. With
the different study days expected to give differences in
results, the analysis was carried out by days 1, 2, 3 and on the
mean of days 1–3. To analyse VAS scores by time point, a
similar linear mixed model was used incorporating terms in
the model for treatment, phase, randomised group and time
point, and then contrasts used to compare the treatment
groups at the different time points. Statistical testing of the
adverse event rates by treatment (either overall rates,
treatment-related rates or rates for specific types of adverse
events) was performed using generalised estimating equa-
tions logistic regression models. To evaluate whether
there was a carryover effect in the second period by the
randomised sequences, a standard statistical approach by
Jones et al.
33 was used to assess. For all statistical tests, the
significance level was set at 0.05. All analyses were performed
using SAS (Version 9.1.3, SAS Institute, Cary, NC, USA).
Results
In total, 51 individuals were recruited for the study of which
45 were randomised (Table 1). After Phase 1, five discon-
tinued from the study. The reasons for withdrawal were
adverse events (n¼2), dislike of the frozen meals offered
(n¼1) and personal reasons unrelated to the study (n¼2).
Overall, 40 participants completed the entire study; how-
ever, only 35 participants were included in the per-protocol
analyses as 2 participants deviated from the protocol and
3 reported feeling sick, which might affect subjective
appetite ratings. Compliance was high for both groups, with
107% and 97% for the rice flour and PGX groups,
respectively. There was no carryover effect in the second
period by the randomised sequences.
Weight loss was similar between groups over the two
phases (PGX 1.3kg versus placebo 1.4kg; P¼0.376). From
the intent-to-treat analysis (n¼40), the PGX treatment
resulted in a significantly lower mean area under the curve
Table 1 Subject characteristics
Value (range)
Age (years) 38.6±9.1 (20–50)
Weight (kg) 79.8±9.3 (59.4–107.8)
Body mass index (kgm
 2) 29.9±2.8 (25.0–34.8)
Waist circumference (cm) 87.0±7.4 (73.3–106.0)
Three-factor eating questionnaire
a
Cognitive 7.3±3.1 (4.0–25.0)
Uncontrolled eating 21.2±4.6 (5.0–27.0)
Emotional eating 14.3±3.8 (7.0–24.0)
Values are mean±s.d.; n¼45.
aThe Three-Factor Eating Questionnaire
evaluates some aspects of eating behaviours such as cognitive restraint
(i.e., the voluntary control of eating), the tendency to lose control of food
intake when faced with external cues, mood changes or disruptive events
(i.e., disinhibition) and susceptibility to feelings of hunger. In this study, the
Three-Factor Eating-R18V2 questionnaire was used as a means to exclude
those who have potentially disordered eating motivation and to assess
motivation of the participants eligible for the study.
20
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Nutrition and Diabeteson day 3 for prospective consumption (P¼0.018) and a
trend towards significance for hunger (P¼0.059). After
elimination of the protocol deviators (n¼35), a similar
pattern was seen with the differences between groups
stronger with a mean percent change of prospective
consumption at  14.7 (P¼0.017) and hunger at  14.8 on
day 3 (P¼0.048, Table 2). There were no statistical
differences in mean area under the curve for any of the
scores for day 1 or 2, or the mean days 1–3, except for
prospective consumption (P¼0.026). The majority of differ-
ences in subjective ratings between the placebo and PGX
groups at various time points were detected on day 3. PGX
supplementation significantly reduced total appetite, desire
to eat, hunger, prospective consumption, and it was
associated with increased fullness at 2.5h after lunch
(Figure 1); reduced total appetite, desire to eat, hunger and
prospective consumption at 4.5h after lunch (Figure 2) and
reduced total appetite, hunger and prospective consumption
before dinner (Figure 3). Hunger was also reduced at 2.5h
after dinner (Po0.05). For palatability, there was a statisti-
cally significant difference in mean palatability VAS scores by
treatment for each day (Po0.05), with PGX
-supplemented
meals scoring above 50mm, but 5–10mm below mean rice
flour scores (data not shown).
Adverse events reported by both treatment groups are
summarised in Table 3. There was no statistical difference
between the two treatment groups in terms of the adverse
events experience of the participants. Furthermore, the
overall or treatment-related adverse events were similar for
the two treatments.
Discussion
This study demonstrates that adding 5g of PGX to meals at
the start of a low-calorie diet helps manage appetite by
increasing satiety and decreasing prospective consumption
(the amount one thinks one could eat). This effect was not
statistically significant until day 3; however it resulted in
reductions above 10% compared with the control, a
Table 2 Daily and 3-day average comparison of subjective appetite measurements calculated as mean area under the curve in response to placebo or PGX for the
per-protocol subject group
Score Day Placebo PGX % Change P-value
Prospective consumption 1 457.2±29.4 432.5±27.8  5.4 0.358
2 477.9±33.1 427.1±29.6  10.6 0.079
34 7 1 ±32.5 401.8±27.7  14.7 0.017
Average days 1–3 468.6±28.9 420.2±25.9  10.3 0.026
Desire 1 432.5±29.4 428.8±29.1  0.9 0.894
2 456.3 ±34.2 416.9±31.3  8.6 0.273
3 427.7±35 387.9±31.7  9.3 0.280
Average days 1–3 438.6±29.7 410.8±27.8  6.3 0.303
Fullness 1 598.3±40.3 591.6±39.9  1.1 0.832
2 584.5±50.7 574.5±49.8  1.7 0.785
3 614.1±47.2 632.3±48.6 3 0.592
Average days 1–3 598.8±43.8 599±43.9 0 0.996
Hunger 1 431.5±28.6 418.3±27.7  3.1 0.651
2 434.9±33.6 407.6±31.5  6.3 0.429
3 440.4±32.9 375.4±28  14.8 0.048
Average days 1–3 435.6±28.4 400±26.1  8.2 0.162
Total appetite 1 469.8±27.3 458.7±26.7  2.4 0.675
2 475.9±31.8 449.4±30.0  5.6 0.390
3 464.5±31.9 414.3±28.4  10.8 0.106
Average days 1–3 470±27.9 440.4±26.2  6.3 0.215
Abbreviation: PGX, PolyGlycopleX. Note: P-value is from a linear mixed-model fit on log scale of area under curve and adjusting for potential sequence and period
effects in addition to treatment (significance level Po0.05). Values shown are mean±s.e.; n¼35.
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Figure 1 Comparison of 2.5h post breakfast, lunch and dinner mean
hunger and prospective consumption scores of day 3 of the 1000-kcal calorie
diet supplement with either 5g of PGX or placebo at each meal. Values shown
are mean±s.e. (n¼35). *Significantly lower scores with PGX than with the
placebo supplement (Po0.05).
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Nutrition and Diabetesmagnitude which is considered to be of practical relevance.
32
With respect to time of day, PGX was found to exert its
strongest effects in the afternoon and in the evening, reducing
total appetite, hunger, desire to eat and prospective consump-
tion. These results might be particularly helpful in managing
obesity, given reports that food intake tends to be less in the
morning and greater in the afternoon and highly evening in
obese versus normal weight individuals.
34 One explanation for
t h ee f f e c ts e e nw i t hP G Xo nd a y3c o u l db et h ei n c r e a s e df i b r e
load. This particular test day had 7g more dietary fibre and 9–
10g less protein than on day 1 or 2, resulting in a possible
synergistic effect and interaction between the PGX and the
dietary fibre content of the meals. Another possibility may be
t h ec u m u l a t i v ee f f e c t so fP G Xo v e rt i m ew i t ht h ep o t e n t i a lf o r
upregulation of gut-satiety hormone gene expression (such as
proglucagon) via fermentation and production of short-chain
fatty acids in the large bowel.
35
Soluble fibres that are fermentable by gut microbiota and
produce significant quantities of short-chain fatty acids may
contribute to appetite regulation by stimulating the release
of gut-satiety hormones such as peptide YY (PYY) and
glucagon like peptide-1.
36 In a study using Zucker diabetic
rats, PGX consumption was associated with a significant
increase in glucagon like peptide-1 levels.
37 In a 3-week
human tolerance trial, supplementation of regular diets with
10g of PGX per day was associated with higher fasting PYY
levels than placebo control.
38 It has been reported that obese
individuals have lower fasting and postprandial circulating
PYY levels than lean individuals,
39,40 which may result in
impaired satiety and may contribute to the development of
obesity and may hinder weight loss efforts. To produce an
equivalent stimulation of PYY sufficient to promote satiety,
obese individuals need to consume a much greater caloric
load than their lean counterparts.
39 An alternative to a
greater caloric load could be a volumetric, lower energy
dense load from supplementing a meal with PGX to
augment PYY levels and stimulate satiety. Further investiga-
tion of a low-calorie diet supplemented with PGX on
gut-satiety hormones is thus warranted.
Under conditions of fixed energy intake, such as a low-
calorie diet, viscous soluble fibres may also alter the viscosity
of gastrointestinal content resulting in multiple effects on
satiety. A magnetic resonance imaging study by Marciani
et al.
41 showed that a high-viscosity nutrient meal had the
strongest additive effect in gastric distension and delayed
gastric emptying compared with low-viscosity non-nutrient,
low-viscosity nutrient and high-viscosity non-nutrient
meals. Viscous soluble fibres also delay the absorption of
nutrients by thickening the unstirred layer at the gut
mucosal surface. This results in the transport of larger
amounts of nutrients to the ileum and/or distributes
nutrient absorption over a larger intestinal luminal surface
area, leading to a more pronounced inhibitory feedback from
the distal gut and activation of the ileal brake.
42 Other
mediators of the ileal brake include the gut-satiety hormones
PYY and glucagon like peptide-1 and vagal nerve stimula-
tion.
43 The ileal brake is a distal to proximal negative
feedback mechanism that inhibits gastric emptying, prox-
imal gastrointestinal motility and secretion to control the
transit of a meal through the gastrointestinal tract, which
consequently optimises nutrient digestion and absorption.
44
As a highly viscous soluble fibre, PGX may cause a delay in
gastric emptying and/or prolong the transport of nutrients
down the gastrointestinal tract as demonstrated by previous
research on its effects on the glycaemic index (GI). The GI is
a property of carbohydrate-containing food that describes
the rise of blood glucose occurring after a meal. High GI
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Figure 3 Comparison of predinner mean hunger and prospective
consumption scores of day 3 of the 1000-kcal calorie diet supplement with
either 5g of PGX or placebo at each meal. Values shown are mean±s.e.
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Nutrition and Diabetesfoods are classified as being rapidly digested and absorbed
into the bloodstream, resulting in a sharp rise and in a steep
decline of blood glucose after consumption, whereas low GI
foods are broken down more slowly by a slower rate of
digestion and absorption and releasing glucose more gradu-
ally into the bloodstream.
45 When 2.5–5g of PGX was
sprinkled on high and moderate GI foods, it was consistently
shown to be highly effective in significantly reducing their
glycaemic index.
45,46 Influencing the digestive rate of foods
and their blood glucose response may have an important
effect on the perception of satiety. Arumugam et al.
47
examined the effects of high-GI versus low-GI meals on
subjective satiety in overweight and obese women. They
found that the appetite score was 35% higher at 4h after the
high-glycaemic versus low glycaemic breakfast, and that at 3,
4 and 5h after lunch, the appetite score was 30–44% higher
in the high glycaemic condition.
47 Many other short-term
studies (o1 day) have also reported a significant relationship
between the glycaemic response and satiety using foods with
varying glycaemic indices.
48–51 In the present study, the
frozen meals were chosen to represent the average Western
diet with convenient, processed higher GI foods and as such
the effect of PGX supplementation on the study foods’
glycaemic indices might be related to the 28%, 14%, 12%
reduction of total appetite score at 2.5, 4.5, 5h, respectively,
after consuming the lunch on day 3. If however the study
foods had a low GI, PGX may not have exerted as significant
an effect on satiety.
This study was designed to alleviate some potentially
confounding variables in appetite research. The timing of the
test phases was scheduled according to participants’ menstrual
cycle, given that previous research has linked changes in
gastrointestinal function, appetite and energy intake to the
follicular and luteal phases of menstruation.
30 The energy
intake, macronutrient composition, water consumption and
eating schedule for all the meals over the three-diet days were
controlled, demonstrating the effect of PGX on homeostatic
hunger (physiological). Although the effect of PGX on
ad libitum food intake cannot be concluded, prior research
has shown that subjective ratings of appetite appear to be good
indicators of motivation to eat and are predictors of actual food
intake.
31,52,53 However, it should also be mentioned that
appetite ratings have not always been found to correlate with
ad libitum food intake,
10 as many factors influence food intake,
including sensory hedonics, external factors, cognitive issues,
body weight, genes and so on.
54–56
To minimise the effect of palatability on appetite ratings,
women who rated the palatability of the meals low were
excluded. However, a significant difference in palatability
between meals supplemented with PGX and rice flour was
observed on all of the three-diet days. Previous research with
PGX has not found any significant differences in palatability
scores in comparisons with controls.
19,45 Study participants
were advised to sprinkle PGX granules as they ate; however,
the hot microwaved meals for lunch and dinner more than
likely accelerated viscosity development, thereby affecting
texture and palatability. This difference may be related more
to texture than to any gastrointestinal discomforts experi-
enced with PGX, as there was no statistical difference in
adverse events reported between PGX and rice flour.
Although palatability affects appetite,
57,58 this did not
translate into significant differences in subjective appetite
Table 3 Summary of the adverse events (AEs) by treatment allocation
Variable Placebo PGX P-value
Number of participants 38 42
Participants reporting adverse events 13 (34.2%) 12 (28.6%) 0.7
Total adverse events 25 28
Participants reporting treatment-related events 8 (21.1%) 11 (26.2%) 0.34
Total treatment-related Events 19 24
Total adverse events (by severity) Unknown severity 0 0
Mild 5 2
Moderate 13 21
Severe 7 5
Total treatment-related events (by severity) Unknown Severity 0 0
Mild 4 2
Moderate 9 18
Severe 6 4
Participants reporting AEs by type of AE Constipation 3 (7.9%) 1 (2.4%) 0.15
Diarrhea 0 (0.0%) 3 (7.1%) NA
Bloating 4 (10.5%) 8 (19%) 0.07
Flatulence 0 (0.0%) 2 (4.8%) NA
Headache 4 (10.5%) 1 (2.4%) 0.17
Cramping 3 (7.9%) 3 (7.1%) 0.59
Sick/unwell 4 (10.5%) 1 (2.4%) 0.08
Other 3 (7.9%) 7 (16.7%) 0.06
Abbreviation: PGX, PolyGlycopleX. Parentheses denote the percentage from the total number of participants. Some P-values were not possible to compute due to no
events being reported under one of the treatment groups. These are noted as ‘NA’ in the table.
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observed on day 3 may have not been due to the palatability
of the PGX
-supplemented meal. When designing placebo-
controlled trials with PGX, it is difficult to find a comparable
inert substance and completely avoid any potentially
confounding effect. Uncooked rice flour was found to closely
approximate PGX in terms of flavour and texture, and it was
thus judged to be a suitable placebo. However, the presence
of resistant starches may have produced an increase in
fermentation in the control group and dampened the
difference in results between the two interventions.
As an initial investigation, this study was performed over 3
days because of the number of VAS questionnaires dispensed
and strict adherence required for the food and meal
schedule. It was conducted under free-living conditions so
as to mimic people following a structured low-calorie diet in
their regular lives. However, this inherently introduced some
variability in the participants’ environment, occupational
and non-occupational activities, which could have resulted
in diurnal variations in appetite.
59 Furthermore, the diet
during the two test phases was self-administered and even
though compliance of the study supplements was high, the
possibility of noncompliance with the prescribed diets could
not be completely avoided.
In summary, this study indicates that the supplementation
of highly viscous PGX to meals could be a useful weight
management aid during a low-calorie diet to help lessen
feelings of hunger and to moderate food portions. Weight
relapse after consuming a low-calorie diet is a common
outcome of obesity interventions. Therefore, long-term studies
investigating the effects of PGX on subjective appetite and the
maintenance of reduced body weight would be warranted. In
addition, it would be useful to examine the effects of PGX on
biomarkers such as glucagon like peptide-1, PYYand ghrelin to
better understand some of the physiological influences of PGX
on satiety. By virtue of its multiple physiological effects on the
mechanisms of satiety, PGX may be an effective weight-
management aid for low-calorie diets.
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The nutritional composition of the three-day low calorie diet
Quantity Calories Carbohydrate (g) Fibre (g) Protein (g) Fat(g)
Day 1 1004 156 7 55 16
Breakfast 244 38 8 5
Blue Menu granola cereal 0.5 cup 165 30 3 3 2
Milk 2% 150 ml 77 7 5 3
Tea or Coffee brewed 1 cup 2 0.7 0 0
Lunch 340 58 20 3
Blue Menu Chicken Bangkok 1 pkg 230 32 2 19 3
Juice, Orange 1 cup 110 26 2 0
Dinner 420 60 27 8
Blue Menu Chinese Sweet & Sour Chicken 1 pkg 350 60 2 22 2
Marble cheese stick 1 70 0 5 6
Day 2 1002 157 7 54 15
Breakfast 249 41 9 2
Maple Brown Sugar Oatmeal 1 pkg 170 33 3 4 2
Milk 2% 150 ml 77 7 5 0
Tea or Coffee brewed 1 cup 2 0.7 0 0
Lunch 333 57 22 2
Blue Menu Ginger Glazed Chicken 1 pkg 220 32 2 19 2
Blue Menu Multigrain Pretzels 30 g 113 25 1 3 0.3
Dinner 420 59 23 11
Blue Menu Thai Sweet Chili Lemon Grass 1 pkg 350 59 1 18 5
Chicken
Marble cheese stick 1 piece 70 0 5 6
Day 3 1005 166 14 45 20
Breakfast 246 45 9 5
Blue Menu Oatmeal Bagel 1 160 30 5 7 2
Blue Menu Old-Fashioned Peanut Butter 1 tsp 33 1 0.3 1 3
Tea or Coffee brewed 1 cup 2 0.7 0 0
Banana, fresh, medium 1/2 53 13 1.5 1 0.2
Lunch 346 58 14 6
Blue Menu Roasted Vegetable Lasagna 1 pkg 240 33 3 12 6
Banana, fresh, medium 1/2 53 13 1.5 1 0.2
Carrots, baby, fresh 1 cup 53 12 2.5 1 0
Dinner 413 63 22 9
Blue Menu Indian Butter Chicken 1 pkg 370 52 2 21 9
Orange, medium 0.5 43 11 2 1 0
Abbreviations: pkg, package; tsp, teaspoon.
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